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Purpose: Proteases play an essential role in the pathophysiology of inflammatory bowel
disease (IBD), contributing to the intestinal mucosal lesions through the degradation of the
extracellular matrix and alteration of the barrier function. Ulcerative colitis (UC) is char-
acterized by an extensive infiltrate of neutrophils into the mucosa and hence, increased
proteolytic activity. Human neutrophil elastase (HNE) is a serine protease that has been
reported to be increased in UC patients’ intestinal mucosa. Based on our previous studies, we
hypothesized that HNE might induce proteolytic degradation and loss of function of ther-
apeutic monoclonal antibodies in IBD patients.
Patients and Methods: Elastase expression and elastinolytic activity were determined in
mucosal explants from ulcerative colitis patients (n=6) and cultured ex vivo in the presence
or absence of recombinant elafin. Enzymatic digestions of therapeutic monoclonal antibodies
were performed using recombinant HNE and elafin. The integrity of the therapeutic anti-
bodies was evaluated by immunoblotting and protein G binding assay, whereas their TNF-
neutralizing activity was assessed with a reporter cell line.
Results: We found that HNE and its elastinolytic activity were increased in the gut mucosa
of UC patients. We also demonstrated that HNE cleaved biological drugs, impairing the
TNF-α neutralizing capacity of anti-TNF monoclonal antibodies. This proteolytic degrada-
tion was inhibited by the addition of the specific inhibitor, elafin.
Conclusion: Our results suggest that the high level of proteolytic degradation by mucosal
neutrophil elastase, along with a potential imbalance with elafin, contributes to the loss of
function of biologic agents, which are currently used in patients with IBD. These findings
might explain the non-responsiveness of UC patients to therapeutic monoclonal antibodies
and suggest the potential beneficial concomitant use of elafin in this treatment.
Keywords: elastinolytic activity, elafin, anti-TNF, inflammatory bowel disease, biological
drugs
Introduction
Inflammatory bowel disease (IBD), comprising the two major disorders Crohn’s
Disease (CD) and Ulcerative colitis (UC), is a chronic relapsing condition char-
acterized by intestinal inflammation and epithelial injury. IBD is thought to be
triggered by inappropriate activation of the intestinal immune system against the
microbiota in genetically susceptible individuals. However, CD and UC represent
independent clinical entities.1,2 The main difference between CD and UC is that
inflammation in UC is continuous and marked by an extensive infiltrate of neu-
trophils. The primary granules of neutrophils contain elastase and cathepsin G, the
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secondary granules contain collagenase and the tertiary
granules contain metalloproteinases (MMP)-2 and MMP-
9.3,4 These proteases contribute to mucosal lesions through
the digestion of the extracellular matrix and alteration of
the barrier function.5
Human neutrophil elastase (HNE) is a serine protease
that cleaves the extracellular matrix protein elastin. There
is evidence that it also up-regulates a number of pro-
inflammatory cytokines, as HNE-deficient mice have
been shown to be protected against dextran sodium sulfate
(DSS)-induced colitis.6 HNE is naturally inhibited by ela-
fin or trappin-2, a serine protease inhibitor mostly released
by epithelial cells throughout the gastrointestinal tract.7 It
has been reported that transgenic mice over-expressing
elafin do not develop experimental colitis, whereas oral
administration of elafin-expressing lactic acid bacteria
diminishes proteolytic activity in the gut mucosa and,
thus, inflammation in both T cell transfer- and DSS-
induced colitis mouse models.6 Additionally, HNE proteo-
lytic activity has been described to be increased in the
mucosa of UC patients.8,9
Anti-tumor necrosis factor (TNF)-α therapy can result
in marked clinical improvement and macroscopic healing
of the inflamed IBD mucosa. However, a substantial pro-
portion of patients do not respond to these biological
agents. A rate of 20–40% of anti-TNFs’ primary non-
response has been reported in clinical trials, while
10–20% in real-life cohorts.10 Our group has previously
demonstrated that this non-responsiveness is due in part to
the highly proteolytic mucosal microenvironment in IBD,
and that particularly MMP-3 and MMP-12 degrade ther-
apeutic antibodies.11
We have therefore hypothesized that HNE may be part
of the proteolytic mucosal environment in UC, contribut-
ing to the functional degradation of anti-TNF agents. On
this basis, here we explore the presence of HNE in the
intestinal mucosa of UC patients and its effect on the
integrity and function of anti-TNF therapeutic drugs.
Patients and Methods
Patients and Tissue
Colonic biopsies were taken from macroscopically and
microscopically inflamed or uninflamed mucosa of adult
patients (mean age 35.3 years, range 25–62) affected by
CD (n=6) or UC (n=12). The diagnosis was made accord-
ing to clinical and histological criteria, and the site and
extent of the disease were confirmed by endoscopy.
Endoscopic disease activity in UC patients was assessed
according to the Mayo score (n=1 Score 0, n=1 Score 1,
n=4 Score 2 and n=6 Score 3).12 In addition, mucosal
samples were collected endoscopically from the colon of
a total of 10 adult subjects who were not diagnosed with
IBD nor any other inflammatory condition of the gut, and
constituted the “healthy control patient” group (HC).
Peripheral venous blood from UC patients and healthy
volunteers was also collected. The study was carried out
in accordance with the Declaration of Helsinki. Each
patient who took part in the study was recruited after
appropriate local Ethics Committee approval (National
Research Ethics Service, East London Research Ethics
Committee 2; REC study number 10/H0704/74) and
informed written consent was obtained in all cases.
Organ Culture
Endoscopic mucosal biopsies from UC and CD patients and
control subjects were weighed and then placed (one biopsy
per well) in 24-well plates (VWR International,
Lutterworth, UK). Individual biopsies were cultured in
300 μL of serum-free HL-1 medium (Lonza, Slough, UK),
supplemented with 100 U/mL penicillin and 100 μg/mL
streptomycin, and cultured at 37ºC, 5% CO2, with or with-
out 5 µg/mL of human recombinant elafin (Sigma-Aldrich,
St.Luis, USA). After 24 h of ex vivo culture, supernatants
of mucosal biopsies were collected and stored at
−70º C until used. All biopsies were lysed in ice-cold
RIPA buffer (Sigma-Aldrich, St.Luis, USA). The protein
concentration was determined using the Bradford Protein
Assay (Bio-Rad Laboratories, Hemel Hempstead, UK).
Elastin and Elafin Specific Assays
Elastin was detected and quantified in mucosal homoge-
nates and supernatants of the organ cultures described
above, using a commercial colorimetric assay (FastinTM-
Elastin; Biocolor-Ltd, UK) according to the manufacturer’s
instructions. Elafin was detected in mucosal homogenates
by Western blot. Briefly, 20 µg of total protein from homo-
genates were run on 10% SDS-PAGE gels under reducing
conditions and subsequently transferred to a nitrocellulose
membrane (Bio-Rad Laboratories, Hemel Hempsted, UK).
Mouse anti-elafin antibody (1:10 dilution, ab81681 Abcam,
UK) was used as the primary antibody, followed by
a horseradish peroxidase-conjugated goat anti-mouse Ig
secondary antibody (1:1000 dilution, Dako, Ely, UK). The
elafin content was quantified in the mucosal homogenates
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using a specific ELISA kit (R&D Systems, Abingdon, UK),
according to the manufacturer’s instructions.
Elastase Activity Assay
Elastinolytic activity was measured in mucosal homoge-
nates after ex vivo culture in HL-1 medium for 24h with or
without 5 µg/mL recombinant elafin (Sigma-Aldrich, St
Luis, USA). Protein homogenates were obtained, and the
elastase activity was measured at different time points
using the EnzCheck Elastase Assay kit (Invitrogen,
Paisley, UK), following the manufacturer’s instructions.
Neutrophil Isolation from the Blood
Polymorphonuclear granulocytes were separated from
whole blood using the commercial mixture of Sodium
diatrizoate and Dextran 500 solution Lympholyte®-poly
(Cedarlane Corporation, Burlington, Canada) according
to the manufacturer´s instructions. Isolated cells were
then lysed in ice-cold RIPA buffer (Sigma-Aldrich, St.
Luis, USA). The protein concentration was determined
using the Bradford Protein Assay (Bio-Rad Laboratories,
Hemel Hempstead, UK).
Cleavage Reactions
Recombinant human neutrophil elastase (HNE) (Athens
Research & Technology, USA) was incubated with different
biological agents to assess its effect on drug integrity and
function. Infliximab (Remicade; Merck Sharp & Dohme
Limited, Hoddesdon, UK and Remsima, Napp
Pharmaceuticals Ltd., Cambridge, UK), adalimumab
(Humira; Abbott Laboratories, Chicago, IL, USA), etaner-
cept (Enbrel; Wyeth, Maidenhead, UK) or vedolizumab
(Entyvio, Takeda Pharmaceuticals, Deerfield, IL, USA)
(all at a concentration of 0.1 µg/mL) were incubated for
24 h at 37°C with increasing concentrations of recombinant
HNE (0 to 10 µg/mL) in HNE buffer (100 mM Tris-HCl,
pH 7.5), with or without 5 µg/mL elafin (Sigma-Aldrich,
USA). Similarly, 1 µg/mL infliximab was co-incubated with
increasing concentrations of blood neutrophil protein
extracts from UC and HC donors (0–5 µg/mL), with or
without 5 µg/mL elafin. The protease activity was stopped
by snap freezing.
Immunoblotting
The effect of HNE on the integrity of the biologic drugs was
assessed by immunoblotting. Cleavage reaction products
were run on 10% SDS-PAGE gels under denaturing condi-
tions and then transferred onto a nitrocellulose membrane
(Bio-Rad Laboratories, Hemel Hempsted, UK). Rabbit anti-
human immunoglobulin Fc antibody (1:2000 dilution,
#31142 Thermo Fisher Scientific Massachusetts, USA) was
used as the primary antibody, followed by a horseradish
peroxidase-conjugated goat anti-rabbit immunoglobulins
secondary antibody (1:3000 dilution, Dako, Ely, UK).
Band density was quantified using ImageJ software
(National Institutes of Health, Bethesda, MD, USA).
Protein-G Binding Assay
The effect of recombinant HNE on the Fc region of the
biological agents was assessed by protein-G binding assay.
Untreated or HNE-treated drugs were added onto a protein-
G-coated 96-well plate (Fisher Scientific Loughborough,
UK). Because chicken antibodies are unable to bind to
protein-G, chicken anti-human p75 TNF-receptor antibody
(Abcam, Cambridge, UK), previously conjugated with
horseradish peroxidase using the Easy link HRP conjugation
kit (Abcam, Cambridge, UK), was added in order to detect
etanercept bound to the coated plate. In parallel, horseradish
peroxidase-conjugated chicken anti-human F(ab’)2 (Fisher
Scientific Loughborough, UK) was added to detect plate-
bound infliximab or adalimumab. Tetramethyl benzidine
(TMB) was used as the substrate, and the optical density
of the color reaction was measured on a plate reader
(BioTek, Swindon, UK).
Luciferase Reporter Assay
The effect of recombinant HNE on the integrity and func-
tion of anti-TNF agents was assessed using a HeLa repor-
ter cell line, stably transfected with the luciferase reporter
gene under the control of nuclear factor-κB enhancer
elements.13 HeLa cells were cultured for 6 h with 10 ng/
mL recombinant human TNF-α (R&D Systems,
Abingdon, UK), which was pre-incubated for one hour
with the HNE-cleaved infliximab, adalimumab or etaner-
cept. Untreated anti-TNF agents, HNE and DMEM were
also pre-incubated with human recombinant TNF-α and
included as controls. After culture, HeLa cells were lysed,
and luciferase activity was detected with a luminescence
microplate reader using Bright-Glo™ Luciferase Assay
System substrate (Promega UK, Southampton, UK).
Statistical Analysis
Data were analyzed with GraphPad Prism software (San
Diego, CA, USA) and using the unpaired or paired two-
tailed t-test and the Mann–Whitney U-test, depending on the
assay. A p-value <0.05 was considered statistically significant.
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Results
Human Neutrophil Elastase Activity Is
Increased in UC Patients’ Mucosa Along
with Lower Content of Elastin
In order to evaluate specific proteolytic activity in IBD
mucosa, HNE enzymatic activity was measured in mucosal
explants homogenates from UC (n=6) and HC (n=6) patients.
UC colonic homogenates showed a significant increasing
enzymatic activity over time compared with samples from
HC (Figure 1A). As HNE is a specific protease for the
extracellular matrix component elastin, we quantified the
content of elastin in biological samples. We found that biopsy
homogenates from UC patients contained lower amounts of
elastin than those from HC mucosa (p<0.01) (Figure 1B).
Elafin Reduces Elastase Activity ex vivo
Considering that elafin is the natural inhibitor of elastase, we
first evaluated whether this inhibitor was present in IBD
mucosa. Elafin was detected in mucosal homogenates from
three representative IBD and three representative healthy
control patients by Western blot, and then by ELISA (n=6
UC, n=6 CD and n=6 HC; Figure 2A). We found signifi-
cantly higher amounts of elafin in IBD patient samples
compared to HC. After the addition of human recombinant
elafin to the ex vivo culture for 24 h, elastase enzymatic
activity was diminished in mucosal homogenates
(Figure 2B); mainly in biopsies from UC patients (n=11,
p<0.05). Additionally, the presence of soluble elastin frag-
ments was assessed in supernatants from UC (n=11) and HC
(n=6) cultured samples (Figure 2C). We observed that UC
biopsies cultured ex vivo released more soluble elastin frag-
ments than HC biopsies, and the addition of elafin signifi-
cantly reduced the elastin fragment release in UC mucosa
organ culture.
Recombinant HNE Degrades Biological
Therapeutic Drugs
The effect of HNE on the integrity of TNF-α neutralizing
agents and the anti-integrin antibody vedolizumab was
evaluated by immunoblotting. First, we optimized the
digestion time (0 to 24 hours) with the highest concentra-
tion of HNE (10 µg/mL) on the different drugs
(Figure 3A). Then we tested 24 hours of digestion with
10 µg/mL HNE (Figure 3B). Figure 3 shows the dose-
dependent enzymatic effect of increasing amounts of
HNE on infliximab, adalimumab, etanercept, and vedoli-
zumab (0.1 µg/mL) during 24 hours at 37°C. The proteo-
lytic products were analyzed by immunoblotting under
reducing conditions using an anti-human IgG Fc primary
antibody. As shown in Figure 4, the heavy chains of
infliximab, adalimumab, and vedolizumab appeared as
a single band of approximately 55 kilodaltons (kDa)
that remained intact after 24 hours of co-incubation
with HNE buffer (0 µg/mL HNE). Adalimumab and
vedolizumab were partially cleaved by different
Figure 1 Elastase enzymatic activity is increased in ulcerative colitis mucosa. (A) Elastase activity in mucosal homogenates from UC (n=6) and HC (n=6) patients, after
24 h culture ex vivo. DQ-Elastin was used as the substrate, and fluorescence was measured over time. Data are plotted as mean ± standard deviation; *p<0.05 and **p<0.01
compared to HC median relative fluorescence units (RFU). (B) Elastin content in the same mucosal homogenates, determined by a colorimetric elastin assay, with
concentrations calculated based on a standard curve and to the total amount of protein in the lysates (elastin µg/mg of protein). Data are plotted as mean ± standard
deviation, **p<0.01 compared to HC median elastin concentration.
Abbreviations: UC, ulcerative colitis; HC, healthy control.
Curciarello et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Journal of Inflammation Research 2020:13236
concentrations of HNE, resulting in 38 and 17 kDa-
fragments, and 25 kDa-fragments, respectively, which
likely correspond to Fc monomers, Fab monomers and
a result of non-enzymatic fragmentation under the dena-
turing conditions of IgG1, respectively.14 Infliximab’s
heavy chain was completely cleaved by the highest con-
centrations of HNE tested. Fragments of 45, 38, 25, and
12 kDa were observed in the blots. Etanercept was
entirely degraded by the highest concentration of HNE,
producing fragments of approximately 32 and 12 kDa.
Densitometry analysis of bands revealed that increasing
concentrations of HNE degraded the biologics from 6%
to 99.9%. However, when recombinant elafin was added,
cleavage reactions were inhibited. Infliximab and adali-
mumab were also degraded after 24 h co-incubation with
increasing concentrations of blood neutrophil protein
homogenates from UC or HC subjects. Multiple bands
were observed by Western blot, including the IgG Fc
monomers of approximately 30 kDa (Figure 5A). In
addition, recombinant elafin specifically inhibited the
proteolysis, as bands corresponding to low molecular
weight fragments were not detected (Figure 5B).
Loss of Fc fraction of the therapeutic monoclonal anti-
bodies was also evaluated by ELISA performed on pro-
tein-G-coated plates. Infliximab, adalimumab, etanercept,
or vedolizumab treated with HNE (for 24 h) or HNE plus
elafin were incubated in the protein G-coated wells. We
found that almost 80% of infliximab and etanercept bind-
ing, and 40 to 50% of adalimumab and vedolizumab
binding to protein G was impaired by HNE digestion.
The binding capacity of the four drugs to protein G was
significantly rescued by elafin (Figure 6).
Figure 2 Elafin is increased in IBD mucosa and inhibits elastase activity ex vivo. (A) Elafin was quantified by ELISA in mucosal homogenates from HC (n=6), UC (n=6), and
CD (n=6) patients. Data are plotted as median ± standard deviation; *p<0.05 and **p<0.01 compared to HC. The immunoblot shows the detection of elafin in three
representative mucosal samples from each group (20µg of protein were loaded). (B) Elastase activity in mucosal homogenates after 24 h of ex vivo culture either untreated
or with 1 µM recombinant elafin. DQ-Elastin was used as the substrate, and fluorescence was measured at 120 min endpoint. Enzymatic specific activity is expressed as RFU/
mg of tissue from UC n=11 and HC n=6 organ cultures. Data are plotted as median ± standard deviation; *p<0.05. (C) Soluble elastin fragments were measured in the
supernatants of the same organ culture conditions as in B, by colorimetric assay with concentrations calculated based on a standard curve and to the total amount of protein
in the lysates (elastin µg/mg of protein). Data are plotted as median ± standard deviation, *p<0.05 compared to the absence of recombinant elafin (medium only) in culture.
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Cleavage of Anti-TNF Agents by HNE
Impairs Their Functional Capacity in vitro
Finally, we investigated whether HNE degradation also
affected the ability of anti-TNF biologics to neutralize
soluble TNF-α using a TNFR-HeLa reporter cell line.
Intact infliximab, adalimumab, and etanercept effectively
inhibited TNF-α-induced luciferase activity of the reporter
cell line. Neutralization of TNF-α with HNE-treated inflix-
imab, adalimumab, or etanercept was significantly reduced
compared to the untreated biologics, an effect that was
reversed by the addition of elafin (Figure 7A). Soluble
TNF-α is not degraded by any components of the cell
culture medium nor by HNE (Figure 7B).
Discussion
Proteases play an essential role in gastrointestinal homeosta-
sis and barrier function, and their activity is tightly regulated
by natural endogenous inhibitors.15–17 However, there is
increasing evidence suggesting that a deregulation of the
protease/anti-protease balance in the gut contributes to gas-
trointestinal diseases such as colorectal cancer, inflammatory
bowel disease, and irritable bowel syndrome.18 In the
inflamed gut, cell infiltration and activation take place in
the mucosa, and this is a source of proteases, which are
released to degrade extracellular tissue. Neutrophils in parti-
cular release large amounts of elastase, proteinase-3, and
cathepsin G.19,20 Increased systemic and intestinal neutrophil
activity has been found in inflamed UC mucosa, rather than
in CD, driving tissue damage (ulceration and crypt
abscesses).21,22 While several studies have shown that the
expression of a very large number of proteases is up-
regulated in inflamedmucosa from patients with IBD, reports
considering their enzymatic activity are scarce.15,23
In this study, we have investigated the enzymatic activ-
ity of neutrophil elastase in the mucosa of UC patients,
along with its specific inhibition by elafin ex vivo. It has
been reported that elastase and elastinolytic activity are
increased in IBD, contributing to ECM remodelling.24,25
Elastase degrades elastin, which is a crucial component of
the extracellular matrix.26,27 Here, we have shown that
there is a higher and increasing elastinolytic activity in
UC mucosa compared to uninflamed healthy control
mucosa, leading to decrease in elastin content within the
tissue. However, the elastase specific inhibitor elafin has
been found surprisingly increased in mucosal homogenates
from IBD patients, reflecting the usual unbalanced rela-
tionship proteases/anti-proteases that contributes to gut
diseases. Even though elafin is increased in these mucosal
explants, it is not enough to compensate for excessive
elastinolytic activity. Our data suggest that the addition
of exogenous elafin ex vivo to organ cultures can redress
this imbalance as we have found that elastase activity in
UC mucosa was inhibited by the effect of exogenous
elafin, preventing elastin degradation. Our data demon-
strate that elastase in inflamed mucosa is sensitive to the
suppressive effect of elafin.
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Figure 3 Evaluation of the optimal enzymatic digestion time and effect of HNE on biologic agents. (A) Representative immunoblotting of the time-course digestion of the
drugs with 10 µg/mL HNE. Adalimumab Western blot is shown after digestion with HNE. Untreated adalimumab at 0 and 24 h was run as control for spontaneous or
temperature degradation. (B) Western blot analysis of infliximab, adalimumab, etanercept and vedolizumab (1 µg/mL) treated with elastase (10 µg/mL HNE) with or without
elafin (5 µg/mL) for 24 h at 37ºC. Relative molecular weights are shown on the left (kDa).
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Apart from protease-specific substrates, we studied the
effect on therapeutic monoclonal antibodies used in UC and
CD patients. Immunoglobulins are sensitive to proteases, and
various studies have demonstrated IgG degradation. In addi-
tion, immunoglobulin cleavage sites have been identified for
several endogenous and also bacterial proteases.28–30 The
degradation of intestinal immunoglobulins is not only relevant
for the loss of function of IgG or IgA exerted by the micro-
biota, but also for the cleavage of exogenous immunoglobulins
used as therapeutic biologic drugs. Our group has previously
demonstrated that MMP-3 and -12 in the inflamed mucosa of
CD and UC patients contribute to the degradation and the loss
of function of infliximab, adalimumab, and etanercept, which
are Fcγ1-containing TNF-blocking agents.11 Infliximab and
adalimumab are monoclonal IgG1 antibodies specific for
TNF-α, etanercept is a dimeric p75 TNF receptor–IgG Fc
fusion protein and vedolizumab is a monoclonal IgG1 specific
for α4β7 integrin.31,32 Based on the deregulated elastinolytic
activity found in the mucosa of UC patients, we further inves-
tigated the effect of human recombinant neutrophil elastase on
different biologic anti-TNF drugs and the anti-integrin vedo-
lizumab. We observed a dose-dependent degradation of inflix-
imab, adalimumab, and vedolizumab, resulting in Fc
monomers and small size fragments of human IgG1. The
addition of elafin inhibited the production of the small frag-
ments, reflecting that the therapeutic monoclonal antibodies
remained intact after incubation with an inhibited elastase. The
integrity of the biologic agents was confirmed by protein
Figure 4 Recombinant human neutrophil elastase degrades different therapeutic monoclonal antibodies and elafin prevents this degradation. Immunoblotting analysis of
infliximab, adalimumab, etanercept, and vedolizumab (all at 0.1 µg/mL) treated with increasing concentration of HNE (0–5 µg/mL), with or without recombinant elafin (5 µg/
mL). Relative molecular weights are depicted (kDa). The blot shown is representative of three analyses.
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G capture ELISA.11 Cleaved antibodies were not detected
using the ELISA for Fab or TNFRp75 detection, demonstrat-
ing the proteolytic degradation of these drugs by HNE.
However, in the presence of elafin, intact infliximab, adalimu-
mab and etanercept could be detected in this assay.
Interestingly, neutrophil protein extracts containing native
proteases, isolated from human blood, similarly affected the
integrity of anti-TNF drugs, which was also rescued by elafin.
Overall, we found that HNE cleaved all biologics tested, and
elafin prevented such degradation.
Moreover, all these biologicals were affected by the
in vitro HNE treatment, impairing not only protein integ-
rity but their neutralizing capacity. We used a TNFR-
reporter cell line and found that infliximab, adalimumab,
and etanercept lost their ability to bind soluble TNF-α after
elastase proteolytic degradation. Elafin inhibited the
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Figure 5 Native HNE from blood neutrophils degrades biologics and can be inhibited by recombinant elafin. Immunoblotting analysis of biologics after the treatment for 24
h at 37ºC with increasing concentrations of blood neutrophil protein extract from UC and HC patients. Molecular weights are shown on the right (KDa). (A) Representative
immunoblotting for adalimumab and infliximab digestion. (B) Representative digestion of infliximab with neutrophil protein extracts from one UC patient and one HC donor.
Digestion was carried out with or without elafin (5 µg/mL).
Figure 6 Recombinant HNE affects the protein G binding capacity of therapeutic monoclonal antibodies. Detection of cleaved infliximab, adalimumab, etanercept, and
vedolizumab, after treatment with 10 µg/mL HNE, according to their protein-G binding capacity. Values expressed as a percentage of binding to protein G, mean ± standard
deviation from three independent experiments performed in duplicates (100% of binding corresponds to the untreated drug condition). *** p <0.0001.
Curciarello et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Journal of Inflammation Research 2020:13240
elastinolytic degradation with the concomitant restoration
of the TNF-α-neutralization effect. As the proteolytic site
for cleavage is the threonine 223 residue in the upper-
hinge site of IgG1, the treatment of the TNF-blocking
agents rendered Fab monomers and the Fcγ1 fraction.14
The absence of binding of Fab to soluble TNF might be
explained by a rearrangement of the Fab fragment protein
conformation, thus the Fc fraction being necessary for the
spatial and bivalent capacity of biologics to recognize and
block a cytokine. To reach a similar conclusion for vedo-
lizumab, one should perform a similar study in a cell line
sensitive to α4β7 binding.
In summary, we showed in this study that neutrophil
elastase activity was increased in the mucosa of patients with
UC, contributing to extracellular matrix degradation, although
neutrophil elastase specific inhibitor elafin was highly
expressed. We also demonstrated that elastase affected the
integrity of therapeutic monoclonal antibodies and the fusion
protein etanercept. Specifically, the TNF-α-neutralizing capa-
city of anti-TNF biologics was compromised by HNE. Our
results suggest that the high level of neutrophil elastase and the
imbalance with the specific inhibitor, elafin, in active UC
mucosa reflect the deregulated protease activity occurring in
the inflamed intestinal mucosa and contribute to the loss of
function of different biologic agents which are extensively
used in these patients. Consequently, this might at least par-
tially explain why many UC patients are non-responsive to
biologic treatment.33 Notwithstanding, we could inhibit muco-
sal elastynolitic activity by adding exogenous elafin to mucosa
ex vivo, and elafin protected the biologics from elastase
Figure 7 Recombinant HNE impairs TNF-α neutralizing ability of the anti-TNF-α biologics. (A) Luciferase activity from a TNFR cell line expressed as a percentage (%)
referred to the highest luminescence induced by TNF-α positive stimulus. TNFR-reporter HeLa cells were stimulated for 6 hours with TNF-α, which had been previously
incubated (1h at 37ºC) with HNE-treated infliximab, adalimumab, or etanercept, with or without elafin. Cells incubated with TNF-α for 1 hour served as a positive control.
Mean ± standard deviation; three independent experiments performed in triplicates. *p <0.05, **p <0.01, ***p <0.001 and, ****p <0.0001. (B) HNE does not degrade TNF-α:
TNF-α was pre-incubated with or without HNE and then added as stimuli on the TNFR-reporter HeLa cell line, as control of TNF degradation by HNE. Medium (untreated)
was included as a negative control to detect basal luminescence of these cells. Luciferase activity is expressed as a percentage (%). Mean ± standard deviation; three
independent experiments performed in triplicates. ****p <0.0001.
Abbreviation: ns, not significant.
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degradation in vitro. Taking into account that the administra-
tion of protease inhibitors has been proposed as a potential
treatment for IBD, and the recent advances in the development
of a personalized treatment that targets an underlying genetic
or microbial origin of the disease, complementation of anti-
inflammatory biologic therapy with exogenous elafin should
be considered as an option for UC patients.34,35
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